{"created":"2025-03-03T05:53:06.571796+00:00","id":2000355,"links":{},"metadata":{"_buckets":{"deposit":"5340ef8a-e7e8-4d31-8b15-7e3a227667c5"},"_deposit":{"created_by":4,"id":"2000355","owner":"4","owners":[4],"pid":{"revision_id":0,"type":"depid","value":"2000355"},"status":"published"},"_oai":{"id":"oai:hama-med.repo.nii.ac.jp:02000355","sets":["1:75:1740964477960"]},"author_link":[],"control_number":"2000355","item_3_biblio_info_5":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2025-03-15","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"1","bibliographicPageEnd":"29","bibliographicPageStart":"25","bibliographicVolumeNumber":"5","bibliographic_titles":[{"bibliographic_title":"浜松医科大学小児科学雑誌","bibliographic_titleLang":"ja"},{"bibliographic_title":"Hamamatsu Journal of Pediatrics","bibliographic_titleLang":"en"}]}]},"item_3_description_9":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"バロキサビルは2018年に発売された新規の抗インフルエンザウイルス薬であり，即時型アレルギーの報告は少ない．12歳女児がインフルエンザA型に罹患した際，初めてバロキサビルを服用し，服用75分後に全身の膨疹と咳嗽が誘発された．2か月後に実施した皮膚プリックテスト（バロキサビル 10mg/mL）は陰性だったが，薬物誘発試験（バロキサビル 40mg）では，内服75分後に咳嗽，喘鳴，および全身の膨疹が出現し，即時型薬物アレルギーと診断した．本症例を通じて，バロキサビルが初回服用でも即時型アレルギー反応を誘発する可能性があることを周知する目的で報告する．","subitem_description_language":"ja","subitem_description_type":"Abstract"},{"subitem_description":"Baloxavir, a new anti-influenza virus drug, was released in 2018. Reports of immediate allergic reactions are rare, and the underlying mechanism of allergy remains unknown. A 12-year-old girl with influenza A was administered baloxavir for the first time and developed a generalized urticarial rash and cough after 75minutes. The skin prick test for baloxavir (10mg/mL) yielded a negative result. However, a drug provocation test with baloxavir (40mg) was conducted, and 75minutes after dosing, the patient developed coughing, wheezing, and a generalized urticarial rash, leading to a diagnosis of immediate allergy. Despite the absence of prior sensitization, immediate-type allergy should be considered as a differential diagnosis, even upon the first administration."}]},"item_3_publisher_6":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"浜松医科大学小児科学雑誌編集部","subitem_publisher_language":"en"}]},"item_3_source_id_20":{"attribute_name":"EISSN","attribute_value_mlt":[{"subitem_source_identifier":"2436-2433","subitem_source_identifier_type":"EISSN"}]},"item_3_version_type_32":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_970fb48d4fbd8a85","subitem_version_type":"VoR"}]},"item_access_right":{"attribute_name":"アクセス権","attribute_value_mlt":[{"subitem_access_right":"open access","subitem_access_right_uri":"http://purl.org/coar/access_right/c_abf2"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorAffiliations":[{"affiliationNameIdentifiers":[{"affiliationNameIdentifier":"0000000089376696","affiliationNameIdentifierScheme":"ISNI","affiliationNameIdentifierURI":"https://isni.org/isni/0000000089376696"},{"affiliationNameIdentifier":"00ndx3g44","affiliationNameIdentifierScheme":"ROR","affiliationNameIdentifierURI":"https://ror.org/00ndx3g44"}],"affiliationNames":[{"affiliationName":"浜松医科大学","affiliationNameLang":"ja"},{"affiliationName":"ハママツイカダイガク","affiliationNameLang":"ja-Kana"},{"affiliationName":"Hamamatsu University School of Medicine","affiliationNameLang":"en"}]}],"creatorNames":[{"creatorName":"中川, 瑞","creatorNameLang":"ja","creatorNameType":"Personal"},{"creatorName":"ナカガワ, ミズキ","creatorNameLang":"ja-Kana","creatorNameType":"Personal"},{"creatorName":"NAKAGAWA, Mizuki","creatorNameLang":"en","creatorNameType":"Personal"}]},{"creatorNames":[{"creatorName":"犬塚, 祐介","creatorNameLang":"ja","creatorNameType":"Personal"},{"creatorName":"イヌヅカ, ユウスケ","creatorNameLang":"ja-Kana","creatorNameType":"Personal"},{"creatorName":"INUZUKA, Yusuke","creatorNameLang":"en","creatorNameType":"Personal"}]},{"creatorNames":[{"creatorName":"加藤, 由希子","creatorNameLang":"ja","creatorNameType":"Personal"},{"creatorName":"カトウ, ユキコ","creatorNameLang":"ja-Kana","creatorNameType":"Personal"},{"creatorName":"KATOH, Yukiko","creatorNameLang":"en","creatorNameType":"Personal"}]},{"creatorNames":[{"creatorName":"安岡, 竜平","creatorNameLang":"ja","creatorNameType":"Personal"},{"creatorName":"ヤスオカ, リュウヘイ","creatorNameLang":"ja-Kana","creatorNameType":"Personal"},{"creatorName":"YASUOKA, Ryuhei","creatorNameLang":"en","creatorNameType":"Personal"}]},{"creatorNames":[{"creatorName":"夏目, 統","creatorNameLang":"ja","creatorNameType":"Personal"},{"creatorName":"ナツメ, オサム","creatorNameLang":"ja-Kana","creatorNameType":"Personal"},{"creatorName":"NATSUME, Osamu","creatorNameLang":"en","creatorNameType":"Personal"}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_access","date":[{"dateType":"Available","dateValue":"2025-03-14"}],"displaytype":"detail","filename":"hjop_5_1_25.pdf","filesize":[{"value":"713 KB"}],"format":"application/pdf","mimetype":"application/pdf","url":{"objectType":"fulltext","url":"https://hama-med.repo.nii.ac.jp/record/2000355/files/hjop_5_1_25.pdf"},"version_id":"57972221-21e9-4067-a713-9be0f2a3e309"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"抗インフルエンザウイルス薬","subitem_subject_language":"ja","subitem_subject_scheme":"Other"},{"subitem_subject":"薬物アレルギー","subitem_subject_language":"ja","subitem_subject_scheme":"Other"},{"subitem_subject":"薬物誘発試験","subitem_subject_language":"ja","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"jpn"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"バロキサビル（ゾフルーザ®）の即時型アレルギーの1例","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"バロキサビル（ゾフルーザ®）の即時型アレルギーの1例","subitem_title_language":"ja"},{"subitem_title":"A Case Report of Immediate Allergy to Baloxavir (Xofluza®) Confirmed by Drug Provocation Test","subitem_title_language":"en"}]},"item_type_id":"3","owner":"4","path":["1740964477960"],"pubdate":{"attribute_name":"PubDate","attribute_value":"2025-03-15"},"publish_date":"2025-03-15","publish_status":"0","recid":"2000355","relation_version_is_last":true,"title":["バロキサビル（ゾフルーザ®）の即時型アレルギーの1例"],"weko_creator_id":"4","weko_shared_id":-1},"updated":"2025-03-14T04:14:57.884463+00:00"}